- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Inscripta Inc.
Headquarters: Boulder, CO, United States of America
Website: http://www.inscripta.com
Year Founded: 2015
Status: Private
BioCentury | Aug 9, 2023
Management Tracks
Baum returns as Mirati CEO as Meek departs
Plus: Voyager hires Shafer as CBO and updates from X4 and Mekonos
BioCentury | Apr 25, 2023
Management Tracks
Sanofi’s Silvestri joins Ipsen as CMO
Plus: Malier leaving Kurma and updates from Harmony, ImmunoGen, Tarsus and more
BioCentury | Apr 8, 2021
Finance
Venture rounds for Icosavax, Nucleix, Vizgen, Inscripta, Metagenomi and Volastra
Vaccine developer Icosavax Inc. raised $100 million in a series B round led by RA Capital Management. New investors Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant
BioCentury | Nov 3, 2020
Management Tracks
Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more
Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE).
BioCentury | Dec 11, 2019
Financial News
Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine
BioCentury | Nov 20, 2019
Finance
With Foresite backing $90M round, GenapSys rolls out a smaller, cheaper sequencer
An opportunity for decentralized sequencing attracted Foresite to lead GenapSys' $90M series C
BioCentury | Dec 21, 2018
Financial News
Inscripta adds $30M to series C to speed use of its gene editing tools
BioCentury | Dec 19, 2018
Financial News
Inscripta adds $30M to series C to speed use of its gene editing tools
Items per page:
1 - 10 of 15